ArticleBreast care (Basel, Switzerland)2022

Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.

Qian Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.